AD_____

Award Number: DAMD17-03-1-0429

TITLE: Proteomic Analysis to Identify Novel Circulating Breast Cancer Markers

PRINCIPAL INVESTIGATOR: Francisco J. Esteva, M.D., Ph.D.

و الما ال

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, Texas 77030

REPORT DATE: June 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040917 093

REPORT DOCUMENTATION PAGE			0	Form Approved OMB No. 074-0188	
Public reporting burden for this collection of infor the data needed, and completing and reviewing reducing this burden to Washington Headquarter	mation is estimated to average 1 hour per response his collection of information. Send comments regal is Services, Directorate for Information Operations a Pariet (024) 0489. Weaking the Dec Services	e, including the time for reviewing in rding this burden estimate or any o and Reports, 1215 Jefferson Davis	structions, searching ex ther aspect of this collec Highway, Suite 1204, Ar	sting data sources, gathering and maintain tion of information, including suggestions fo lington, VA 22202-4302, and to the Office	
Management and Budget, Paperwork Reduction 1. AGENCY USE ONLY	Project (0704-0188), Washington, DC 20503 2. REPORT DATE	3. REPORT TYPE AND	DATES COVERE	ĒD	
(Leave blank)	June 2004	Annual (27 May	- 2003 - 26	May 2004)	
<i>4. TITLE AND SUBTITLE</i> Proteomic Analysis to Cancer Markers	Identify Novel Circula	ting Breast	5. FUNDING N DAMD17-03	<i>UMBERS</i> -1-0429	
<i>6.AUTHOR(S)</i> Francisco J. Esteva, M	1.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas M.D. Anderson Cancer Center Houston, Texas 77030		8. PERFORMING ORGANIZATION REPORT NUMBER			
E-Mail: festeva@mdander	cson.org				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDR	ESS(ES)		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
U.S. Army Medical Rese Fort Detrick, Maryland	earch and Materiel Comm 1 21702-5012	and			
			<u> </u>		
12a. DISTRIBUTION / AVAILABILI Approved for Public Re	TY STATEMENT elease; Distribution Un	limited		12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 W	ords)		· _ · · · · · · · · · · · · · · ·		
The purpose of our proposed wor breast cancer, and to discover now women and 100 breast cancer pat	k is to study differences in serum provel tumor markers. We intend to gen ients. The goal of this analysis is to it tinguish women with breast cancer f	otein expression profiles erate proteomics spectra identify serum proteomic	between healthy on serum sample patterns using a origin and full it	women and women with s from 100 healthy matrix-assisted laser	
desorption ionisation that can dis discriminating proteins or peptide The protocol is under review by the Command. I received their first re- concerns on January 30, 2004. In am still waiting for the final appr	es will be investigated. he Office of Regulatory Compliance eview of the protocol and informed of received a second review with addition oval of the protocol and informed co	and Quality at U.S. Arm consent on January 21, 20 onal comments on June 1 nsent. I was informed th	ny Medical Resea 004, and replied t 1, 2004 and I repl at I can't initiate	dentity of the arch and Materiel o their comments and ied on June 10, 2004. I this study until I receive	
desorption ionisation that can dis discriminating proteins or peptide The protocol is under review by t Command. I received their first re concerns on January 30, 2004. I n am still waiting for the final appr approval through the USAMRAA 14. SUBJECT TERMS Breast neoplasms, prot	es will be investigated. he Office of Regulatory Compliance eview of the protocol and informed of received a second review with addition oval of the protocol and informed co A Contracting Office. Therefore, I has contracting Office. Therefore, I has ceomics, serum, tumor m	arkers biologica	ny Medical Resea 004, and replied t 1, 2004 and I repl at I can't initiate t the present time	arch and Materiel o their comments and ied on June 10, 2004. I this study until I receive 15. NUMBER OF PAGES 4 16. PRICE CODE	
desorption ionisation that can dis discriminating proteins or peptide The protocol is under review by t Command. I received their first re concerns on January 30, 2004. I r am still waiting for the final appr approval through the USAMRAA 14. SUBJECT TERMS Breast neoplasms, prot 17. SECURITY CLASSIFICATION OF REPORT	es will be investigated. he Office of Regulatory Compliance eview of the protocol and informed of received a second review with addition oval of the protocol and informed contracting Office. Therefore, I has contracting Office. Therefore, I has teomics, serum, tumor matching 18. SECURITY CLASSIFICATION OF THIS PAGE Uppel ages if i od	arkers biologica	ny Medical Resea 004, and replied t 1, 2004 and I repl at I can't initiate t the present time FICATION	tentity of the arch and Materiel o their comments and ied on June 10, 2004. I this study until I receive 15. NUMBER OF PAGES 4 16. PRICE CODE 20. LIMITATION OF ABSTRAC	

Table of Contents

• •

Cover1
SF 2982
Table of Contents3
Introduction4
Body4
Key Research Accomplishments4
Reportable Outcomes4
Conclusions4
References4
Appendices

Introduction

The purpose of our proposed work is to study differences in serum protein expression profiles between healthy women and women with breast cancer, and to discover novel tumor markers. We intend to generate proteomics spectra on serum samples from 100 healthy women and 100 breast cancer patients. The goal of this analysis is to identify serum proteomic patterns using a matrix-assisted laser desorption ionisation that can distinguish women with breast cancer from healthy women. The origin and full identity of the discriminating proteins or peptides will be investigated.

Body

The protocol is under review by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I received their first review of the protocol and informed consent on January 21, 2004, and replied to their comments and concerns on January 30, 2004. I received a second review with additional comments on June 1, 2004 and I replied on June 10, 2004.

Key Research Accomplishments

N/A

Reportable Outcomes

·N/A

Conclusions

We are awaiting the final approval of the protocol and informed consent by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I was informed that I can't initiate this study until I receive approval through the USAMRAA Contracting Office. Therefore, I have no results to report at the present time.

References

N/A